4-(dimethylamino)-1-(4-nitrophenyl)-1-butanone | 607713-62-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(dimethylamino)-1-(4-nitrophenyl)-1-butanone
• 英文别名: 4-dimethylamino-1-(4-nitrophenyl)butan-1-one；4-(Dimethylamino)-1-(4-nitrophenyl)butan-1-one
• CAS: 607713-62-2
• 化学式: C₁₂H₁₆N₂O₃
• 分子量: 236.271
• InChiKey: YSGGUFONLMBODX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(dimethylamino)-1-(4-nitrophenyl)-1-butanone 在 ammonium acetate 、 sulfur 、 溶剂黄146 、 二乙胺 作用下， 以 乙醇 、 苯 为溶剂， 反应 19.5h， 生成 2-amino-5-[2-(dimethylamino)ethyl]-4-(4-nitrophenyl)-3-thiophenecarbonitrile
  参考文献：
  名称：

  Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).

  DOI：

  10.1021/jm050458h
• 作为产物：
  描述：

  4-{[tert-butyl (dimethyl)silyl]oxy}-1-(4-nitrophenyl)butan-1-one 在 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 4-(dimethylamino)-1-(4-nitrophenyl)-1-butanone
  参考文献：
  名称：

  Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).

  DOI：

  10.1021/jm050458h

文献信息

• Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
  申请人：——

  公开号：US20040014756A1

  公开（公告）日：2004-01-22

  Compounds having the formula 1 are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors
  申请人：Michaelides R. Michael

  公开号：US20060276490A1

  公开（公告）日：2006-12-07

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还揭示了制备该化合物的方法，含有该化合物的组合物以及使用该化合物的治疗方法。
• Verfahren zur Herstellung von wässrigen Diazoniumsalzlösungen
  申请人：Clariant GmbH

  公开号：EP1052248A1

  公开（公告）日：2000-11-15

  Eine wäßrige Lösung von Diazoniumsalzen wird in Abwesenheit organischer Lösemittel hergestellt, indem eine wasserlösliche aromatische Nitroverbindung in wäßriger Lösung mit Wasserstoff und einem Hydrierkatalysator zur aromatischen Aminoverbindung reduziert und diese in der wäßrigen Lösung diazotiert wird.

  重氮盐的水溶液是在无有机溶剂的情况下，将水溶液中的水溶性芳香族硝基化合物用氢气和氢化催化剂还原成芳香族氨基化合物，并在水溶液中重氮化而制备的。
• THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP1487841B1

  公开（公告）日：2014-01-15
• US6207809B1
  申请人：——

  公开号：US6207809B1

  公开（公告）日：2001-03-27